Skip to main content

Skin Health & Dermatology

Discovery Services

Select Service Type

SKIN HEALTH

  • Fibroblasts/Keratinocytes proliferationDRF/CB/SHP-01

    Fibroblasts/Keratinocytes proliferation to evaluate Skin rebuild & repair using Fibroblasts (HFF-1)/ Keratinocytes (HaCaT), measuring percent proliferation by BrdU.

    • Cell Model

      Fibroblasts (HFF-1)/ Keratinocytes (HaCaT)

    • End Point

      Percent Proliferation by BrdU

    • Reference Drugs

      L-Ascorbic Acid

    • Relevance

      Skin rebuild & repair
  • ECM synthesis [Collagen, Elastin, Hyaluronic acid (HA)] in fibroblastsDRF/CB/SHP-02

    ECM synthesis [Collagen, Elastin, Hyaluronic acid (HA)] in fibroblasts to evaluate Skin texture (strength, durability) using Fibroblasts (HFF-1), measuring percent modulation of Elastin/ HA/ Collagen levels.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Percent modulation of Elastin/ HA/ Collagen levels

    • Reference Drugs

      L-Ascorbic Acid

    • Relevance

      Skin texture (strength, durability)
  • Fibroblast/Keratinocytes MigrationDRF/CB/SHP-03

    Fibroblast/Keratinocytes Migration to evaluate Skin rebuild & repair, Wound healing using Fibroblasts (HFF-1)/ Keratinocytes (HaCaT), measuring percent migration.

    • Cell Model

      Fibroblasts (HFF-1)/ Keratinocytes (HaCaT)

    • End Point

      Percent migration

    • Reference Drugs

      L-Ascorbic Acid

    • Relevance

      Skin rebuild & repair, Wound healing
  • Skin inflammation - Cytokine and chemokine release in fibroblasts/keratinocytesDRF/CB/SHP-04

    Skin inflammation - Cytokine and chemokine release in fibroblasts/keratinocytes to evaluate Skin soothing and calming effects using Fibroblasts (HFF-1)/ Keratinocytes (HaCaT), measuring inhibition of cytokines as compared to damage.

    • Cell Model

      Fibroblasts (HFF-1)/ Keratinocytes (HaCaT)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Skin soothing and calming effects
  • MMPs Inhibition in fibroblastsDRF/CB/SHP-05

    MMPs Inhibition in fibroblasts to evaluate Skin protection from damage using Fibroblasts (HFF-1), measuring inhibition of MMPs as compared to damage.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Inhibition of MMPs as compared to damage

    • Reference Drugs

      Ascorbic Acid/ Resveratrol

    • Relevance

      Skin protection from damage
  • Inhibition of Elastase activityDRF/CB/SHP-06

    Inhibition of Elastase activity to evaluate Skin elasticity using Elastase Enzyme (cell free), measuring Elastase Activity.

    • Cell Model

      Elastase Enzyme (cell free)

    • End Point

      Elastase Activity

    • Reference Drugs

      Oleanolic acid

    • Relevance

      Skin elasticity
  • Inhibition of Hyaluronidase activityDRF/CB/SHP-07

    Inhibition of Hyaluronidase activity to evaluate Skin moisturization & hydration using Keratinocytes (HaCaT), measuring hyaluronidase activity.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Hyaluronidase activity

    • Reference Drugs

      EGCG

    • Relevance

      Skin moisturization & hydration
  • Lipid synthesis in keratinocytesDRF/CB/SHP-08

    Lipid synthesis in keratinocytes to evaluate Skin moisturization & hydration using Keratinocytes (HaCaT), measuring lipid content by Oil O red assay.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Lipid content by Oil O red assay

    • Reference Drugs

      Linolic acid

    • Relevance

      Skin moisturization & hydration
  • Skin barrier - Formation of Corneal Epithelium in keratinocytesDRF/CB/SHP-09

    Skin barrier - Formation of Corneal Epithelium in keratinocytes to evaluate Skin barrier improvement using Keratinocytes (HaCaT), measuring Improvement of skin barrier function by formation of cornified envelope.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Improvement of skin barrier function by formation of Cornified envelope

    • Reference Drugs

      α-Tocopherol/EGF

    • Relevance

      Skin barrier improvement

STRETCH MARKS

  • Proteolytic enzyme - ChymotrypsinDRF/CB/SHP-10

    Proteolytic enzyme - Chymotrypsin to evaluate Anti-proteolytic using Cell-free, measuring chymotrypsin activity.

    • Cell Model

      Cell-free

    • End Point

      Chymotrypsin activity

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol/ EGCG

    • Relevance

      Anti-proteolytic
  • Proteolytic enzyme - TrypsinDRF/CB/SHP-11

    Proteolytic enzyme - Trypsin to evaluate Anti-proteolytic using Cell-free, measuring trypsin activity.

    • Cell Model

      Cell-free

    • End Point

      Trypsin activity

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol/ EGCG

    • Relevance

      Anti-proteolytic
  • Proteolytic enzyme - ElastaseDRF/CB/SHP-12

    Proteolytic enzyme - Elastase to evaluate Anti-proteolytic using Cell-free, measuring elastase activity.

    • Cell Model

      Cell-free

    • End Point

      Elastase activity

    • Reference Drugs

      Oleanolic acid

    • Relevance

      Anti-proteolytic
  • Stimulation of collagen in fibroblastsDRF/CB/SHP-13

    Stimulation of collagen in fibroblasts to evaluate Skin strengthening using Fibroblasts (HFF-1), measuring percent modulation of Collagen levels.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Percent modulation of Collagen levels

    • Reference Drugs

      L-Ascorbic Acid

    • Relevance

      Skin strengthening
  • Stimulation of fibronectin in fibroblastsDRF/CB/SHP-14

    Stimulation of fibronectin in fibroblasts to evaluate Skin strengthening using Fibroblasts (HFF-1), measuring percent modulation of Fibronectin levels. Reference drugs include L-Ascorbic Acid.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Percent modulation of Fibronectin levels

    • Reference Drugs

      L-Ascorbic Acid

    • Relevance

      Skin strengthening

ANTI-AGING

  • Cytoprotection against oxidative stress in fibroblasts (HFF-1)DRF/CB/AA-01

    Cytoprotection against oxidative stress in fibroblasts (HFF-1) to evaluate Antiaging/Anti-wrinkling using Fibroblasts (HFF-1), measuring restoration of cell viability.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Antiaging/Anti-wrinkling
  • Antiapoptotic effect against oxidative stress in fibroblasts (HFF-1)DRF/CB/AA-02

    Antiapoptotic effect against oxidative stress in fibroblasts (HFF-1) to evaluate Antiaging/Anti-wrinkling using Fibroblasts (HFF-1), measuring restoration of cell viability.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Anti-aging/Anti-wrinkling
  • Reactive oxygen species (ROS) generation/quenchingDRF/CB/AA-03

    Reactive oxygen species (ROS) generation/quenching to evaluate Antioxidant/ Antiaging/Anti-wrinkling using Fibroblasts (HFF-1), measuring modulation of ROS levels.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Modulation of ROS levels

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Antioxidant/ Anti-aging/Anti-wrinkling
  • Cyclobutane Pyrimidine Dimer (CPD) formation in fibroblastDRF/CB/AA-04

    Cyclobutane Pyrimidine Dimer (CPD) formation in fibroblast to evaluate Cytoprotection using Fibroblasts (HFF-1), measuring modulation of CPD formation.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Modulation of CPD formation

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Cytoprotection
  • Anti-senescence effect by shortening of doubling time of human fibroblasts (WI-38)/Hayflick limitDRF/CB/AA-05

    Anti-senescence effect by shortening of doubling time of human fibroblasts (WI-38)/Hayflick limit in Human fibroblasts (WI-38) to study cellular aging.

    • Cell Model

      Human fibroblasts (WI-38)

    • End Point

      Doubling Time/ Hayflick number

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Cellular aging
  • Senescence associated beta-galactosidase activity in diploid fibroblastDRF/CB/AA-06

    Senescence associated beta-galactosidase activity in diploid fibroblast in Fibroblasts (HFF-1) to study cellular aging.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      beta-galactosidase activity

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Cellular aging
  • Telomerase activity in cellsDRF/CB/AA-07

    Telomerase activity in cells to evaluate cellular aging using Fibroblasts (HFF-1)/ Keratinocytes (HaCaT), measuring Telomerase activity.

    • Cell Model

      Fibroblasts (HFF-1)/ Keratinocytes (HaCaT)

    • End Point

      Telomerase activity

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Cellular aging
  • Telomere lengthDRF/CB/AA-08

    Telomere length to evaluate cellular aging using Fibroblasts (HFF-1)/ Keratinocytes (HaCaT), measuring telomere length.

    • Cell Model

      Fibroblasts (HFF-1)/ Keratinocytes (HaCaT)

    • End Point

      Telomere Length

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Cellular aging
  • SIRT-1 modulation in cellsDRF/CB/AA-09

    SIRT-1 modulation in cells to evaluate cellular aging using Fibroblasts (HFF-1)/ Keratinocytes (HaCaT), measuring SIRT-1 activity.

    • Cell Model

      Fibroblasts (HFF-1)/ Keratinocytes (HaCaT)

    • End Point

      SIRT-1 activity

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Cellular aging
  • Comet assay in cellsDRF/CB/AA-10

    Comet assay in cells to evaluate cellular aging using Fibroblasts (HFF-1), measuring Comet length.

    • Cell Model

      Fibroblasts (HFF-1)

    • End Point

      Comet length

    • Reference Drugs

      L-Ascorbic Acid/ Resveratrol

    • Relevance

      Cellular aging

PSORIASIS

  • Inhibition of proliferation of keratinocytes (HaCaT)/Immune cellsDRF/CB/DP-01

    Inhibition of proliferation of keratinocytes (HaCaT)/Immune cells to evaluate Anti-proliferative using Keratinocytes (HaCaT), measuring inhibition of cell proliferation.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Inhibition of cell proliferation

    • Reference Drugs

      Dithranol, Methotrexate, Curcumin

    • Relevance

      Anti-proliferative
  • Apoptosis in keratinocytes (HaCaT)DRF/CB/DP-02

    Apoptosis in keratinocytes (HaCaT) to evaluate apoptosis using Keratinocytes (HaCaT), measuring Anti-apoptotic potential against damage.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      Curcumin

    • Relevance

      Apoptosis
  • Cytokines inhibition in keratinocytes (HaCaT)/Immune cellsDRF/CB/DP-03

    Cytokines inhibition in keratinocytes (HaCaT)/Immune cells to evaluate Inflammation using Keratinocytes (HaCaT)/ Human Monocytic cells (THP-1), measuring Inhibition of cytokines as compared to stimulation.

    • Cell Model

      Keratinocytes (HaCaT)/ Human Monocytic cells (THP-1)

    • End Point

      Inhibition of cytokines as compared to stimulation

    • Reference Drugs

      Dexamethasone/ Methotrexate/ Curcumin/ Dimethyl fumarate/ Cyclosporin A

    • Relevance

      Inflammation
  • Vascular endothelial growth factor (VEGF) Inhibition in keratinocytesDRF/CB/DP-04

    Vascular endothelial growth factor (VEGF) Inhibition in keratinocytes to evaluate Inflammation/ Angiogenesis using Keratinocytes (HaCaT), measuring inhibition of VEGF as compared to stimulation.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Inhibition of VEGF as compared to stimulation

    • Reference Drugs

      Curcumin, Methotrexate, Dexamethasone

    • Relevance

      Inflammation/ Angiogenesis
  • IL-17/IL-23 inhibitionDRF/CB/DP-05

    IL-17/IL-23 inhibition to evaluate Inflammation using Human Monocytic cells (THP-1), measuring inhibition of cytokines as compared to stimulation.

    • Cell Model

      Human Monocytic cells (THP-1)

    • End Point

      Inhibition of cytokines as compared to stimulation

    • Reference Drugs

      Dexamethasone

    • Relevance

      Inflammation

ATOPIC DERMATITIS (AD)/ECZEMA

  • Inhibition of cytokines release (TSLP, TARC, MDC/CCL22, VEGF, IL-6, IL-8) by keratinocytesDRF/CB/DP-06

    Inhibition of cytokines release (TSLP, TARC, MDC/CCL22, VEGF, IL-6, IL-8) by keratinocytes to evaluate Anti-eczema/AD using Keratinocytes (HaCaT), measuring inhibition of cytokines as compared to stimulation.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Inhibition of cytokines as compared to stimulation

    • Reference Drugs

      Curcumin, Methotrexate, Dexamethasone

    • Relevance

      Anti-eczema/AD
  • Strengthening of skin barrier (Cornified envelope) in keratinocytes (HaCaT)DRF/CB/DP-07

    Strengthening of skin barrier (Cornified envelope) in keratinocytes (HaCaT) to evaluate Anti-eczema/AD using Keratinocytes (HaCaT), measuring improvement of skin barrier function by formation of Cornified envelope.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Improvement of skin barrier function by formation of Cornified envelope

    • Reference Drugs

      α-Tocopherol/EGF

    • Relevance

      Anti-eczema/AD
  • Increase in markers of differentiation (Filaggrin, Involucrin, Loricrin, Aquaporin-3) in keratinocytes (HaCaT)DRF/CB/DP-08

    Increase in markers of differentiation (Filaggrin, Involucrin, Loricrin, Aquaporin-3) in keratinocytes (HaCaT) in Keratinocytes (HaCaT) to study Anti-eczema/AD.

    • Cell Model

      Keratinocytes (HaCaT)

    • End Point

      Increase in surface marker proteins from basal levels

    • Reference Drugs

      α-Tocopherol

    • Relevance

      Anti-eczema/AD
  • IgE inhibition in myeloma cellsDRF/CB/DP-09

    IgE inhibition in myeloma cells to evaluate Anti-prutitis using B-myeloma cells (U266B1), measuring IgE levels.

    • Cell Model

      B-myeloma cells (U266B1)

    • End Point

      IgE levels

    • Reference Drugs

      Dexamethasone

    • Relevance

      Anti-prutitis

SKIN WHITENING/ VITILIGO

  • Melanogenesis assay in melanocytes (B16F10)DRF/CB/DP-14

    Melanogenesis assay in melanocytes (B16F10) to evaluate Skin fairness/Anti-vitiligo using Melanocytes (B16F10), measuring melanin Content.

    • Cell Model

      Melanocytes (B16F10)

    • End Point

      Melanin Content

    • Reference Drugs

      Kojic acid/ alpha-MSH/ IBMX

    • Relevance

      Skin fairness/Anti-vitiligo
  • Tyrosinase assay (mushroom tyrosinase)DRF/CB/DP-15

    Tyrosinase assay (mushroom tyrosinase) to evaluate Skin fairness/Anti-vitiligo using melanocytes (B16F10), measuring tyrosinase enzyme activity.

    • Cell Model

      Melanocytes (B16F10)

    • End Point

      Tyrosinase enzyme activity

    • Reference Drugs

      Kojic acid/ alpha-MSH/ IBMX

    • Relevance

      Skin fairness/Anti-vitiligo
  • Migration of melanocytes (B16F10)DRF/CB/DP-16

    Migration of melanocytes (B16F10) to evaluate Skin fairness/Anti-vitiligo using Melanocytes (B16F10), measuring percent modulation of migration.

    • Cell Model

      Melanocytes (B16F10)

    • End Point

      Percent modulation of migration

    • Reference Drugs

      Kojic acid/ alpha-MSH/ IBMX

    • Relevance

      Skin fairness/Anti-vitiligo
  • Cytoprotection against oxidative stress in melanocytes (B16F10)DRF/CB/DP-17

    Cytoprotection assessment against oxidative stress in melanocytes (B16F10) to study skin fairness and anti-vitiligo effects, using melanocytes (B16F10)

    • Cell Model

      Melanocytes (B16F10)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      Kojic acid/ alpha-MSH/ IBMX

    • Relevance

      Skin fairness/Anti-vitiligo

ANTI-ACNE

  • Inhibition of proliferation in sebocytesDRF/CB/DP-10

    Inhibition of proliferation in sebocytes to evaluate Anti-proliferative effect using Sebocytes (SebE6E7), measuring Proliferation inhibition by MTT assay.

    • Cell Model

      Sebocytes (SebE6E7)

    • End Point

      Proliferation inhibition by MTT assay

    • Reference Drugs

      Resveratrol/ Isotretinoin

    • Relevance

      Anti-proliferative
  • Lipid synthesis in sebocytes by Oil Red O stainingDRF/CB/DP-11

    Lipid synthesis in sebocytes/ keratinocytes by Oil Red O staining to evaluate Sebostatic activity using Sebocytes (SebE6E7), measuring lipid content by OIL O Red assay.

    • Cell Model

      Sebocytes (SebE6E7)

    • End Point

      Lipid content by OIL O Red assay

    • Reference Drugs

      Isotretinoin

    • Relevance

      Sebostatic activity
  • Cytokines inhibition in sebocytesDRF/CB/DP-12

    Cytokines inhibition in sebocytes to evaluate Inflammation using Keratinocytes (HaCaT), measuring Inhibition of cytokines as compared to stimulation.

    • Cell Model

      Sebocytes (SebE6E7)

    • End Point

      Inhibition of cytokines as compared to stimulation

    • Reference Drugs

      Dexamethasone/ Methotrexate/ Curcumin

    • Relevance

      Inflammation
  • Antimicrobial activity against P acnesDRF/CB/DP-13

    Antimicrobial activity against P acnes to evaluate Anti- P acnes activity using P.acne, measuring MIC/ MBC.

    • Cell Model

      P.acne

    • End Point

      MIC/ MBC

    • Reference Drugs

      Clindamycin

    • Relevance

      Anti- P acnes activity

DERMATOLOGY

  • Anti-psoriatic Potential in Imiquimod (IMQ)-induced skin inflammation modelPCY/DER-01

    Anti-psoriatic potential in Imiquimod-induced skin inflammation in Balb/c mice, measuring cytokine levels and clinical score.

    • Animal Model

      Balb/c Mice

    • End Point

      Cytokine (IL-23, IL-17, TNF-α etc..) levels in serum & skin, Clinical score, Biopsy weight, Histology of skin

    • Reference Drugs

      Betamethasone
  • Anti-psoriatic Potential using TPA induced Skin Inflammation ModelPCY/DER-02

    Anti-psoriatic potential using TPA-induced skin inflammation in Balb/c mice, assessing cytokine levels, biopsy weight, and histology.

    • Animal Model

      Balb/c Mice

    • End Point

      Cytokine levels in serum & skin, Clinical score, Biopsy weight, Histology of skin

    • Reference Drugs

      Betamethasone
  • Antiseborrheic / Anti-Acne activity using Hamster flank gland modelPCY/DER-03

    Anti-seborrheic/anti-acne activity using hamster flank gland model, measuring flank gland size and triglyceride levels.

    • Animal Model

      Hamster

    • End Point

      Flank gland size/area, Scoring, Triglyceride and IL1 alpha level in flank tissue, Histology

    • Reference Drugs

      Tretinoin
  • Atopic Dermatitis Using Oxazolone modelPCY/DER-04

    Atopic dermatitis using oxazolone model in BALB/c mice, measuring cytokine levels and clinical score.

    • Animal Model

      BALB/c Mice

    • End Point

      Cytokine (IFN-γ, TNF-α, IL-5, etc...) levels in serum & skin, Clinical score, Biopsy weight, Histology of skin

    • Reference Drugs

      Betamethasone, Tacrolimus
  • Antipruritic effect using histamine-induced itching modelPCY/DER-05

    Antipruritic effect using histamine-induced itching model in BALB/c mice, measuring scratch frequency and serum histamine levels.

    • Animal Model

      BALB/c Mice

    • End Point

      No. of scratch % Activity, Serum histamine

    • Reference Drugs

      Anti-histaminic
  • Diabetes induced non healing open wound modelPCY/DER-06

    Diabetes-induced non-healing open wound model in rats, measuring wound area, growth factors, and histology.

    • Animal Model

      Wistar/ SD Rat

    • End Point

      Wound Area, Wound Contraction, Growth factor (Collagen, KGF & VEGF) in skin tissue, Skin Histology

    • Reference Drugs

      `--
  • Wound healing activity in Incision modelPCY/DER-07

    Wound healing activity in an incision model in rats, assessing growth factors and histology.

    • Animal Model

      Wistar/ SD Rat

    • End Point

      Growth factor (KGF & VEGF) in skin tissue Skin Histology

    • Reference Drugs

      Silver Sulfadiazine
  • Wound healing activity in Excision modelPCY/DER-08

    Wound healing activity in an excision model in rats, assessing wound contraction and histology.

    • Animal Model

      Wistar/ SD Rat

    • End Point

      Wound Area, Wound Contraction, Growth factor (Collagen, KGF & VEGF) in skin tissue, Skin Histology

    • Reference Drugs

      Silver Sulfadiazine
  • Wound healing activity in Scratch wound modelPCY/DER-09

    Wound healing activity in a scratch wound model in rats, evaluating wound score, shedding, and histology.

    • Animal Model

      Wistar/ SD Rat

    • End Point

      Skin Histology, Wound Score, Photograph,Shedding

    • Reference Drugs

      Crack Cream
  • Pressure - wound (Bed sore) modelPCY/DER-10

    Pressure wound (bed sore) model in rats, assessing wound score and growth factors.

    • Animal Model

      Wistar/ SD Rat

    • End Point

      Wound Score, Growth actor (VEGF & KGF) in skin tissue Skin Histology

    • Reference Drugs

      Phenytoin
  • Anti-vitiligo activity using monobenzone induced vitiligo ModelPCY/DER-11

    Anti-vitiligo activity using monobenzone-induced vitiligo model in C57BL/6 mice, assessing vitiligo score, biomarkers, and histopathology.

    • Animal Model

      C57BL/6 Mice

    • End Point

      Images, Vitiligo score, Key immune, biomarkers, Histopathology & IHC of affected skin etc.

    • Reference Drugs

      Pigmento Ointment